• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体阳性、人表皮生长因子受体2阴性浸润性乳腺癌患者超声特征与21基因复发评分检测之间的关联

Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.

作者信息

Chae Eun Young, Moon Woo Kyung, Kim Hak Hee, Kim Won Hwa, Cha Joo Hee, Shin Hee Jung, Choi Woo Jung, Han Wonshik, Noh Dong-Young, Lee Sae Byul, Ahn Sei Hyun

机构信息

Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Republic of Korea.

Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.

出版信息

PLoS One. 2016 Jun 30;11(6):e0158461. doi: 10.1371/journal.pone.0158461. eCollection 2016.

DOI:10.1371/journal.pone.0158461
PMID:27362843
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4928814/
Abstract

A multigene expression assay corresponds to the likelihood of breast cancer recurrence after the initial diagnosis and can be used to guide the decision for additional chemotherapy. However, only few studies have investigated the associations between the imaging features of breast cancer and the results of multigene expression assays. Our study was to identify the relationship between imaging features on ultrasound (US) and the recurrence score (RS) on a 21-gene expression assay in patients with oestrogen receptor (ER)-positive, HER2-negative breast cancer. 267 patients with ER-positive, HER-negative invasive breast cancer who underwent examinations using US and Oncotype DX assay were included. US images were independently reviewed by dedicated breast radiologists who were blind to the RS. Tumour roundness was measured using a laboratory-developed software program. The pathological data were reviewed, including immunohistochemistry results. Univariate analysis was performed to assess the associations between the RS and each variable. Multiple logistic regression analysis was used to identify independent predictors of high RS. Of 267 patients, 147 (55%) had low, 96 (36%) intermediate, and 24 (9%) had high RS. According to the univariate analysis, parallel orientation, presence of calcification in the mass, and tumour roundness were positively associated with high RS. Multiple logistic regression analysis showed that parallel orientation (OR = 5.53) and tumour roundness (OR = 1.70 per 10 increase) were associated with high RS. Parallel orientation and tumour roundness are independent variables that may predict high RS in patients with ER-positive, HER2-negative breast cancer.

摘要

多基因表达检测与乳腺癌初次诊断后的复发可能性相关,可用于指导是否进行额外化疗的决策。然而,仅有少数研究调查了乳腺癌的影像特征与多基因表达检测结果之间的关联。我们的研究旨在确定雌激素受体(ER)阳性、人表皮生长因子受体2(HER2)阴性乳腺癌患者的超声(US)影像特征与21基因表达检测的复发评分(RS)之间的关系。纳入了267例接受了US检查和Oncotype DX检测的ER阳性、HER阴性浸润性乳腺癌患者。US图像由专门的乳腺放射科医生独立评估,这些医生对RS结果不知情。使用实验室开发的软件程序测量肿瘤的圆形度。审查病理数据,包括免疫组化结果。进行单因素分析以评估RS与每个变量之间的关联。采用多因素logistic回归分析确定高RS的独立预测因素。267例患者中,147例(55%)RS较低,96例(36%)中等,24例(9%)RS较高。根据单因素分析,平行方位、肿块内钙化的存在以及肿瘤圆形度与高RS呈正相关。多因素logistic回归分析显示,平行方位(比值比[OR]=5.53)和肿瘤圆形度(每增加10单位OR=1.70)与高RS相关。平行方位和肿瘤圆形度是可能预测ER阳性、HER2阴性乳腺癌患者高RS的独立变量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee13/4928814/bcbf0e5a4332/pone.0158461.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee13/4928814/bcbf0e5a4332/pone.0158461.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee13/4928814/bcbf0e5a4332/pone.0158461.g002.jpg

相似文献

1
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.雌激素受体阳性、人表皮生长因子受体2阴性浸润性乳腺癌患者超声特征与21基因复发评分检测之间的关联
PLoS One. 2016 Jun 30;11(6):e0158461. doi: 10.1371/journal.pone.0158461. eCollection 2016.
2
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.早期雌激素受体阳性/人表皮生长因子受体2阴性浸润性乳腺癌中部分容积校正后的最大标准化摄取值(SUVmax)与Oncotype DX复发评分之间的关联
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1574-84. doi: 10.1007/s00259-016-3418-1. Epub 2016 May 21.
3
Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.Oncotype DX在双侧同步原发性浸润性乳腺癌中的应用
Ann Surg Oncol. 2016 Feb;23(2):471-6. doi: 10.1245/s10434-015-4841-4. Epub 2015 Sep 4.
4
Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?在去除 HER2 阳性和低雌激素受体表达的患者后,Oncotype DX 复发评分(RS)是否具有预后价值?
Breast J. 2013 Jul-Aug;19(4):357-64. doi: 10.1111/tbj.12126. Epub 2013 May 23.
5
The Prognostic Significance of the Oncotype DX Recurrence Score in TNM Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition.基于第 8 版 AJCC 预后分期的 Oncotype DX 复发评分在 TNM 雌激素受体阳性 HER2 阴性乳腺癌中的预后意义。
Ann Surg Oncol. 2019 May;26(5):1227-1235. doi: 10.1245/s10434-018-7068-3. Epub 2018 Nov 19.
6
Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer.Oncotype DX 复发评分与雌激素受体阳性 HER2 阴性浸润性乳腺癌患者动态对比增强 MRI 特征的相关性。
Clin Imaging. 2021 Jul;75:131-137. doi: 10.1016/j.clinimag.2021.01.021. Epub 2021 Jan 20.
7
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.21 基因复发评分与淋巴结阴性、雌激素受体阳性乳腺癌的局部区域复发。
Breast Cancer Res Treat. 2017 Nov;166(1):69-76. doi: 10.1007/s10549-017-4381-7. Epub 2017 Jul 12.
8
The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.石蜡包埋的粗针活检组织的Oncotype DX®复发评分对预测乳腺癌女性新辅助化疗反应的影响。
Breast Dis. 2016 Jul 28;36(2-3):65-71. doi: 10.3233/BD-150199.
9
The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.Oncotype DX 乳腺癌检测结果对临床实践的影响:英国的经验。
Breast Cancer Res Treat. 2020 Apr;180(3):809-817. doi: 10.1007/s10549-020-05578-6. Epub 2020 Mar 13.
10
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?乳腺钼靶和超声成像特征能否预测T1和T2期、激素受体阳性、HER2阴性且腋窝淋巴结阴性乳腺癌的Oncotype DX™复发评分?
Breast Cancer Res Treat. 2014 Nov;148(1):117-23. doi: 10.1007/s10549-014-3143-z. Epub 2014 Sep 28.

引用本文的文献

1
The added value of ultrasound imaging biomarkers to clinicopathological factors for the prediction of high-risk Oncotype DX recurrence scores in patients with breast cancer.超声成像生物标志物对乳腺癌患者高风险Oncotype DX复发评分预测中临床病理因素的附加值。
Quant Imaging Med Surg. 2024 May 1;14(5):3519-3533. doi: 10.21037/qims-23-1620. Epub 2024 Apr 26.
2
Value of Molybdenum Target X-Ray and High-Frequency Color Doppler Flow Imaging in Early Diagnosis of Breast Carcinoma: A Comparative Analysis.钼靶X线与高频彩色多普勒血流成像在乳腺癌早期诊断中的价值:对比分析
Cancer Manag Res. 2023 Oct 16;15:1155-1163. doi: 10.2147/CMAR.S412924. eCollection 2023.
3

本文引用的文献

1
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?乳腺钼靶和超声成像特征能否预测T1和T2期、激素受体阳性、HER2阴性且腋窝淋巴结阴性乳腺癌的Oncotype DX™复发评分?
Breast Cancer Res Treat. 2014 Nov;148(1):117-23. doi: 10.1007/s10549-014-3143-z. Epub 2014 Sep 28.
2
Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.鉴定乳腺癌肿瘤的内在成像表型:与基因表达谱的初步关联。
Radiology. 2014 Aug;272(2):374-84. doi: 10.1148/radiol.14131375. Epub 2014 Apr 4.
3
The Prospects of Using Structural Phase Analysis of Microcalcifications in Breast Cancer Diagnostics.
微钙化的结构相分析在乳腺癌诊断中的应用前景
Diagnostics (Basel). 2023 Feb 15;13(4):737. doi: 10.3390/diagnostics13040737.
4
The Clinical Application of Combined Ultrasound, Mammography, and Tumor Markers in Screening Breast Cancer among High-Risk Women.联合超声、乳腺 X 线摄影和肿瘤标志物在高危女性乳腺癌筛查中的临床应用。
Comput Math Methods Med. 2022 Jul 15;2022:4074628. doi: 10.1155/2022/4074628. eCollection 2022.
5
Imaging features of breast cancer molecular subtypes: state of the art.乳腺癌分子亚型的影像学特征:最新进展
J Pathol Transl Med. 2021 Jan;55(1):16-25. doi: 10.4132/jptm.2020.09.03. Epub 2020 Nov 9.
6
Clinical value of color Doppler ultrasound combined with serum CA153, CEA and TSGF detection in the diagnosis of breast cancer.彩色多普勒超声联合血清CA153、CEA及TSGF检测在乳腺癌诊断中的临床价值
Exp Ther Med. 2020 Aug;20(2):1822-1828. doi: 10.3892/etm.2020.8868. Epub 2020 Jun 10.
7
Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.超声特征与分子亚型与乳腺癌疾病结局的相关性研究。
Cancer Med. 2020 Sep;9(17):6173-6185. doi: 10.1002/cam4.3305. Epub 2020 Jul 13.
8
Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer.具有垂直定向特征的超声检查可预测三阴性乳腺癌的预后更差。
Breast. 2020 Feb;49:33-40. doi: 10.1016/j.breast.2019.10.006. Epub 2019 Oct 23.
9
Gene expression profiling of calcifications in breast cancer.乳腺癌钙化的基因表达谱分析。
Sci Rep. 2017 Sep 12;7(1):11427. doi: 10.1038/s41598-017-11331-9.
Quantitative MRI morphology of invasive breast cancer: correlation with immunohistochemical biomarkers and subtypes.
浸润性乳腺癌的定量MRI形态学:与免疫组化生物标志物及亚型的相关性
Acta Radiol. 2015 Mar;56(3):269-75. doi: 10.1177/0284185114524197. Epub 2014 Feb 20.
4
Assessing the role of ultrasound in predicting the biological behavior of breast cancer.评估超声在预测乳腺癌生物学行为中的作用。
AJR Am J Roentgenol. 2013 Feb;200(2):284-90. doi: 10.2214/AJR.12.8781.
5
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.免疫组化定义的 luminal A 型乳腺癌中孕激素受体阳性肿瘤细胞的预后意义。
J Clin Oncol. 2013 Jan 10;31(2):203-9. doi: 10.1200/JCO.2012.43.4134. Epub 2012 Dec 10.
6
Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse.孕激素受体缺失可识别出复发风险较高的腔面 B 型乳腺癌亚组。
Ann Oncol. 2013 Mar;24(3):661-8. doi: 10.1093/annonc/mds430. Epub 2012 Sep 28.
7
Sonographic appearance of invasive ductal carcinoma of the breast according to histologic grade.根据组织学分级的乳腺浸润性导管癌的超声表现。
AJR Am J Roentgenol. 2012 Sep;199(3):W402-8. doi: 10.2214/AJR.11.7374.
8
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.淋巴结阴性、雌激素受体阳性乳腺癌患者的复发风险和化疗获益:仅复发评分与病理和临床因素相结合。
J Clin Oncol. 2011 Nov 20;29(33):4365-72. doi: 10.1200/JCO.2011.35.3714. Epub 2011 Oct 17.
9
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.亚型策略——应对乳腺癌的多样性:2011 年圣加仑国际乳腺癌专家共识会议关于早期乳腺癌初始治疗的要点。
Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27.
10
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer.用于改善 II 期和 III 期结直肠癌预后预测的基因表达谱。
J Clin Oncol. 2011 Jan 1;29(1):17-24. doi: 10.1200/JCO.2010.30.1077. Epub 2010 Nov 22.